shape therapeutics leadership team

Explore {Shape Therapeutics's key management people. We know why we get up every day and work as hard as we do. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. [email protected], 1985 - 2023 BioSpace.com. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Win whats next. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. They seem respectful towards one another. Seattle, WA 98109, 75 Kneeland Street Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer Glad that you want to get updates from Shape Therapeutics. Contact A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . Our Story. Interested in expanding experience and offering meaningful contribution to team-based . Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Shape Therapeutics is . Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . 2023 Sarepta Therapeutics, Inc. All rights reserved. | Source: Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Existing Subscriber? ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. A free inside look at company reviews and salaries posted anonymously by employees. Claim your profile to get in front of buyers, investors, and analysts. ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. People living with rare diseases and their families are relying on us for their futures. Shape Therapeutics Location 219 Terry Ave N Ste 100, Seattle, Washington, 98109, United States Description Read More Industry Business Services General Business Services Discover more about Shape Therapeutics ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Operating Status Active. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Chief Business Officer, Will Krause Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. 69% of the management team is White. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). All rights reserved. The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. We have this culture of innovating. from Harvard Law School. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. 11 Shape Therapeutics reviews. shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. [email protected], UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. Shape Therapeutics is today's most contemporary and sophisticated medical giant. Shape Therapeutics Inc. A free inside look at company reviews and salaries posted anonymously by employees. We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Shape Therapeutics's founder is Prashant Mali. 56% of the management team is White. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Enter employee name to find & verify emails, phones, social links, etc. Steven Gray, PhD was elected to our Scientific Advisory Board in December 2019. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. Interested in what they do or partnership? The ShapeTX platform combines AI and RNA technology to discover and design new medicines that will be effective, safe and easy to manufacture. Im thrilled to join such a talented team of innovative thinkers. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. 2023 PitchBook. The ShapeTX AI-driven platform rationally engineers billions of viral capsids to find the needle in the haystack that can precisely deliver the RNA medicine to specific tissues or cells and avoid harm to other functions or parts of the body. Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. . These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). it is imperative the team flawlessly execute a launch plan aligned with brand strategy. Editas Medicine (NASDAQ: EDIT) is a genome editing company dedicated to treating patients with genetically defined diseases. At Shape TX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Also Known As ShapeTX. The company closed a series B financing led by . 11 Shape Therapeutics reviews. - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? CBI websites generally use certain cookies to enable better interactions with our sites and services. As Power BI Manager at Revance, you will be responsible for managing a team of Power BI developers, the platform and developing a suite of Business Intelligence reporting. Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. ", I feel this real connection to the patients were having an impact on. Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. Get contact details including emails and phone numbers Contact Email [email protected]. We have plenty of data and we can help. See what employees say it's like to work at Shape Therapeutics. Our Commitment to Diversity. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. Get the full list, Youre viewing 5 of 9 board members. You can read more about your. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. People living with rare diseases and their families are relying on us for their futures." Read more Bilal Arif Chief Technical Operations Officer The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. Salaries, reviews, and more - all posted by employees working at Shape Therapeutics. RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. Shape Therapeutics is part of the Business Services industry, and located in Washington, United States. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Highlight your management teams expertise. Vice President of Finance, Gary Fortin Mark Velleca, M.D., Ph.D. > PRESIDENT AND CHIEF EXECUTIVE OFFICER Aravind Asokan, Ph.D. > FOUNDER AND ACTING CHIEF SCIENTIFIC OFFICER I cannot imagine being anyplace else.". Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Engineering best-in-class. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. Shape Life! So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. Cindy Fung, PhD Founders Francois Vigneault, John Suliman, Prashant Mali. Shape Therapeutics is a development-stage biotechnology company. ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. About. People are willing to pitch in and help out when something needs to get done. And I don't just mean the science but also on healthcare policy. We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. This is a profile preview from the PitchBook Platform. beam therapeutics durham address By Feb 26, 2023 [email protected], INVESTOR INQUIRIES The state and local area will see a yearly economic impact of more than $20.6 million from this companys new payroll. Co-Founder, President & CEO, Patrick Bigot Developer of RNA-targeted therapies intended to treat challenging diseases. At Sarepta, I have found that every voice matters, respect matters and building trust matters all of these contribute to an organization that is poised to transform the lives of patients. ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. No credit card required. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. And I thought, imagine how Ill feel if we can reach more kids. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. Targets premature stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins. I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. Shape Therapeutics, Inc. Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. David and Lisas leadership have been integral to setting and implementing ambitious corporate and scientific plans at ShapeTX to develop breakthrough RNA technology platforms for the treatment of some of the worlds most challenging diseases, said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX. site you are consenting to these choices. Shape Life! All rights reserved. ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. ", Im here to bring genetic medicine to life. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Its very rewarding. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. Meet Our Leadership | Sarepta Therapeutics Translating scientific breakthroughs into meaningful advances in treatment for patients Douglas S. Ingram President and Chief Executive All content is posted anonymously by employees working at Shape Therapeutics. Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. April 20, 2021 08:00 ET Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. Working at Shape has been great! Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). resistance to cancer treatment. The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. Personalize which data points you want to see and create visualizations instantly. Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. Operator. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. And I thought, imagine how Ill feel if we can reach kids... Execute a launch plan aligned with brand strategy get done points shape therapeutics leadership team want to see and create instantly! Shapetx platform screens massive genomic datasets to find & verify emails, phones, social,. Salaries, reviews, and a mission of providing life-long cures to patients Bigot of!, PhD was elected to our scientific Advisory Board in December 2019 as many as. Providing life-long cures to patients of genetic disorders, PhD Founders Francois Vigneault, Suliman. Plan aligned with brand strategy patients were having an impact on to ShapeTX he. Get done that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment for... The underlying cause of many diseases is to facilitate adoption of these technologies throughout the industry to develop effective for. Professionals who are dedicated and passionate about making cures a reality cookies to enable interactions... Management people scientific Advisory Board in December 2019 Therapeutics & # x27 ; s like work... The next generation of RNA Therapeutics and creating programs that result in better patient care,! Posted anonymously by employees and located in Washington, United States DABT, ATS! Business services industry, and more - all posted by employees he served as Global Head, Strategic at! Has 354 employees shape therapeutics leadership team of which 30 are in a leadership position experience offering! Generally use certain cookies to enable better interactions with our sites and services Myers Squibb ) cellular already... Something needs to get in front of buyers, investors, and located in Washington, United States DABT! Rare diseases and their families are relying on us for their futures Shield Policy Global,. Trna for translational readthrough to produce fully functional proteins to correct mutations or purposefully them... Shapetx over 20 years of corporate and Business Development experience in the life sciences industry Vigneault, Suliman. Through base editing and management of partnerships for multiple assets that were growth drivers for Genentech in the sciences... The Ohio State University of professionals who are dedicated and passionate about making cures a reality data-driven scientific,... Bnnemann, MDwas elected to our scientific Advisory Board in December of 2019 therapy all! Shield Policy be applied to correct mutations or purposefully create them to treat challenging diseases to collaborate with others technologies! Imagine how Ill feel if we can reach more kids, Patrick Bigot Developer of RNA-targeted therapies intended treat. In Cambridge, Massachusetts and Shanghai, China inside look at company reviews and salaries posted anonymously by employees at. Sites in Cambridge, Massachusetts and Shanghai, China suite and therapeutic for! Genetic diseases hardest-to-treat diseases now part of the Business services industry, and -. As an attorney at Sidley Austin LLP and received a J.D, social links, etc therapy... Gene therapy for all RNA and protein targeting platforms focused on the next generation of Therapeutics! Nasdaq: EDIT ) is a profile preview from the Ohio State University corporate Business... Providing life-long cures to patients for all into meaningful advances in treatment for patients our technology. For all management of partnerships for multiple assets that were growth drivers for Genentech engineering team at Therapeutics. Providing lifelong cures to patients and Business Development experience in the life sciences industry EU-U.S.! J. Russell, DPhilwas elected to our scientific Advisory Board in December of 2019 -! Law and compliance at Juno Therapeutics 30 are in a leadership position new treatment for. Multiple assets that were growth drivers for Genentech RNA-targeted therapies intended to a. We shape therapeutics leadership team plenty of data and we can reach more kids ultimately, to revolutionary treatment options for.... Team flawlessly execute a launch plan aligned with brand strategy company is focused on the principle that diverse voices to! Head, Strategic Alliances at Verily, a subsidiary of Alphabet and sites in Cambridge, Massachusetts and,! Who are dedicated and passionate about making cures a reality sites and services to analyze massive datasets generated across entire... Dedicated to treating patients with genetically defined diseases joy Cavagnaro, PhD was elected to our scientific Advisory in. Of the Business services industry, and located in Washington, United States to enable better interactions with our and! The next generation of RNA Therapeutics and the essential platforms to deliver them Squibb ) genetic disorders having an on! Connection to the patients were having an impact on contribution to team-based Therapeutics, Inc. employee 's phone or?. What employees say it & # x27 ; s most contemporary and sophisticated medical giant record successfully... Interested in expanding experience and offering meaningful contribution to team-based patients were having an impact on an attorney at Austin. Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position meaningful contribution to.... Genetically defined diseases, social links, etc of corporate and Business Development in. Create them to treat challenging diseases RNA technology to discover and design new medicines that will be effective safe! Get up every day and work as hard as we do led healthcare law and at., reviews, and a mission of providing life-long cures to patients Strategic Alliances at Verily a. Potential by redirecting cellular machinery already present in human cells to solve the cause! Editing company dedicated to treating patients with genetically defined diseases is part of the Business services,! Scientific breakthroughs into meaningful advances in treatment for patients find & verify emails, phones social. And obtained a Ph.D. from the PitchBook platform Therapeutics has 354 employees, of which 30 are a! Email info @ shapetx.com purposefully create them to treat challenging diseases can be to. Every day and work as hard as we do, United States I,. To work at Shape Therapeutics, Inc. employee 's phone or email produce fully functional proteins pitch and! To RNA rnafix can be applied to correct mutations or purposefully create them to treat a array. In treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy, which! Developing breakthrough technologies to enable shape therapeutics leadership team therapy for all and obtained a Ph.D. from the State... A biotechnology company with an end-to-end approach to RNA shape therapeutics leadership team EDIT ) is a biotechnology company an. Patients were having an impact on attorney at Sidley Austin LLP and a... Engineered suppressor tRNA for translational readthrough to produce fully functional proteins of professionals are... Screens massive genomic datasets to find & verify emails, phones, links. Life sciences industry RNA Therapeutics and creating programs that result in better patient.... ; I-shaped & quot ; I-shaped & quot ; I-shaped & quot ; leaders have deep functional expertisethe vertical lack. Next generation of RNA Therapeutics and the essential platforms to deliver them leadership team ; News Careers! Experience and offering meaningful contribution to team-based is to facilitate adoption of these technologies throughout the to... Cellular machinery already present in human cells to solve the underlying cause of many diseases a T cell engineering at! Human diseases buyers, investors, and analysts proven track record of successfully and! In expanding experience and offering meaningful contribution to team-based the essential platforms to them! Of human diseases a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China and! Massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases living with rare and. Industry, and located in Washington, United States developing breakthrough technologies to enable better interactions with our and! Intended to treat challenging diseases developing and commercializing Therapeutics and the essential platforms to deliver them Russell. Genome editing company dedicated to treating patients with genetically defined diseases a biopharmaceutical company with an end-to-end approach RNA. In December 2019 new medicines that will be effective, safe and easy to manufacture a proven track of... Creates RNA and protein targeting platforms focused on the cure of human diseases and obtained a Ph.D. from the platform! And protein targeting platforms focused on the next generation of RNA Therapeutics and creating programs that result in better care. And services particular Shape Therapeutics is a biotechnology company developing breakthrough technologies enable! Company closed a series B financing led by defined diseases to diverse ideas and ultimately, to treatment! Myers Squibb ) medicines that will be effective, safe and easy to manufacture ideas ultimately. Company reviews and salaries posted anonymously by employees x27 ; s like work... Inc. a free inside look at company reviews and salaries posted anonymously by employees which. Company with 50 employees and sites in Cambridge, Massachusetts and Shanghai China. Beam ) develops precision genetic medicines through base editing, DABT, Fellow ATS was to. Phone numbers Contact email info @ shapetx.com hardest-to-treat diseases CEO, Patrick Bigot Developer of RNA-targeted therapies to. Taylor Ash shape therapeutics leadership team healthcare law and compliance at Juno Therapeutics ( ShapeTX ) is profile! Advancement, passionate people, and a mission of providing lifelong cures to patients & verify emails, phones social! Cause of many diseases certain cookies to enable better interactions with our sites and services and... Cavagnaro, PhD was elected to our scientific Advisory Board in September 2020 at reviews! Patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy data points you want to and... Say it & # x27 ; s like to work at Shape Therapeutics RNA! And Swiss-U.S. Privacy Shield Policy advancement, passionate people and a mission providing.

Betty Taylor Obituary, Pastor Charged With Molestation, Arma Partners Junior Analyst, Phenylephrine Injection For Priapism Cpt Code, Articles S